A 5-HT1A agonist and a 5-HT2C antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats

Psychopharmacology

Volumn 167, Issue 4, 2003, Pages 344-352

  Overstreet, David H ^a   Knapp, Darin J ^a   Moy, Sheryl S ^a   Breese, George R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT1A; 5 HT2A receptors; 5 HT2C; Anxiety like behavior; Forced ethanol exposure; Repeated ethanol withdrawals; Social interaction test

Indexed keywords

6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ALCOHOL; BUSPIRONE; KETANSERIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN; RO 601075; SEROTONIN 1A AGONIST; SEROTONIN 2C ANTAGONIST; UNCLASSIFIED DRUG; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; AMINOPYRIDINE DERIVATIVE; ETHYLAMINE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADAPTIVE BEHAVIOR; ALCOHOL WITHDRAWAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SOCIAL INTERACTION; ANIMAL; ANXIETY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; SOCIAL BEHAVIOR; SPRAGUE DAWLEY RAT; WITHDRAWAL SYNDROME;

AMINOPYRIDINES; ANIMALS; ANXIETY; BUSPIRONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; ETHYLAMINES; INDOLES; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; RITANSERIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SOCIAL BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0038575719     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-003-1425-y     Document Type: Article

References (52)

1. Amano M, Goto A, Sakai A, Achita M, Takahashi N, Hara C, Ogawa N (1993) Comparison of the anticonflict effect of buspirone and its major metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in rats. Jpn J Pharmacol 61:311-317
2. Andrews N, File SE (1993) Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supported neurochemical and behavioural evidence. Psychopharmacology 112:21-25
3. 1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4:399-408
4. Ballenger JC, Post RM (1978) Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 133:1-14
5. Berggren U, Eriksson M, Fahlke C, Balldin J (2002) Is long-term heavy alcohol consumption toxic for brain serotonergic neurons? Relationship between years of excessive alcohol consumption and serotonergic neurotransmission. Drug Alcohol Depend 65:159-165
6. Boess FG, Martin H (1994) Molecular biology of 5-HT receptors Neuropharmacology 33:275-317
7. 2C receptor antagonist. Neuropharmacology 36:621-629
8. 1A receptor antagonist, WAY-100635, in the rat. Neuropharmacology 39:123-132
9. Bruno F (1989) Buspirone in the treatment of alcoholic patients. Psychopathology 22:49-59
10. Cao BJ, Rodgers RJ (1997) Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze. Neuropharmacology 36:1089-1097
11. Curran GM Flynn HA, Kirchner J, Booth BM (2000) Depression after alcohol treatment as a risks factor for relapse among male veterans. J Subst Abuse Treat 19:259-265
12. De Soto CB, O'Donnell WE, De Soto JL (1989) Long-term recovery in alcoholics. Alcohol Clin Exp Res 13:693-697
13. Dougherty RJ, Gates RR (1990) The role of buspirone in the management of alcohol withdrawal: a preliminary investigation. J Subst Abuse Treat 7:189-192
14. Driessen M, Meier S. Hill A (2001) The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol Alcohol 36:249-255
15. Fawcett J, Kravitz HM, McGuire M, Easton M, Ross J, Pisani V, Fogg LF, Clark D, Whitney M, Kravitz G, Javaid J, Teas G (1999) Pharmacological treatments for alcoholism: revisiting lithium and considering buspirone. Alcohol Clin Exp Res 24:666-674
16. File SE (1980) The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Meth 2:219-238
17. File SE, Andrews N, al-Farhan M, Wu PY (1993) The role of 5-HT in the anxiogenic effects of acute ethanol withdrawal and in the long-lasting cognitive deficits. Alcohol Alcohol 28:495-499
18. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
19. Frye GD, McCown TJ, Breese GR (1983) Differential sensitivity of ethanol withdrawal signs in the rat to γ-aminobutyric acid (GABA) mimetics: blockade of audiogenic seizures but not forelimb tremors. J Pharmacol Exp Ther 226:720-725
20. George DT, Rawlings R, Eckhardt MJ, Phillips MJ, Shoaf SE, Linnoila M (1999) Buspirone treatment of alcoholism: age of onset, and cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid concentrations, but not medication treatment, predict return to drinking. Alcohol Clin Exp Res 23:272-278
21. 1A receptor function: a link between anxiety and depression? Pharmacol Biochem Behav 59:787-792
22. Hedlund L, Wahlstrom G (1999) Acute and long-term effects of buspirone treatment on voluntary ethanol intake in a rat model of alcoholism. Alcohol Clin Exp Res 23:822-827
23. Kampov-Polevoy AB, Matthews DB, Gause L, Morrow AL, Overstreet DH (2000) P rats develop physical dependence on alcohol via voluntary drinking: changes in seizure thresholds, anxiety, and patterns of alcohol drinking. Alcohol Clin Exp Res 24:278-284
24. 2C receptor antagonist. Neuropharmacology 36:609-620
25. 2C receptor agonist, in three animal models of anxiety. Eur J Pharmacol 387:197-204
26. Knapp DJ, Duncan GE, Crews FT, Breese GR (1998) Induction of Fos-like proteins and ultrasonic vocalizations during ethanol withdrawal: further evidence for withdrawal-induced anxiety. Alcohol Clin Exp Res 22:481-493
27. rd Annual Meeting of the Research Society on Alcoholism, Denver, CO, June 24-29, 2000. Alcohol Clin Exp Res 24:90A
28. th Annual Meeting of Research Society on Alcoholism, Montreal, Canada, June 23-28, 2001. Alcohol Clin Exp Res 25:23A
29. Kranzler H, Meyer RF (1992) An open trial of buspirone in alcoholics. J Clin Psychopharmacol 9:379-380
30. Lal H, Prather PL, Rezazadeh SM (1991) Anxiogenic behavior in rats during acute and protracted ethanol withdrawal: reversal by buspirone. Alcohol 8:467-471
31. 2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res 17:411-417
32. Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16:1007-1013
33. Malec TS, Malec EA, Dongier M (1996) Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res 20:853-858
34. McCown TJ, Breese GR (1990) Multiple withdrawals from ethanol "kindles" inferior collicular seizure activity: evidence for kindling of seizures associated with alcoholism. Alcohol Clin Exp Res 14:394-399
35. Meert TF (1994) Ritanserin and alcohol abuse and dependence. Alcohol Alcohol 2:523-530
36. Miller WR, Harris RJ (2000) A simple scale of Gorski's warning signs for relapse. J Stud Alcohol 61:759-765
37. Moy SS, Knapp DJ, Criswell HE, Breese GR (1997) Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology 131:354-360
38. Moy SS, Knapp DJ, Duncan GE, Breese GR (2000) Enhanced ultrasonic vocalization and Fos protein expression following ethanol withdrawal: effects of flumazenil. Psychopharmacology 152:208-215
39. 2 antagonist, in heavy social drinkers: desire to drink, alcohol intake and related effects. Addiction 90:893-905
40. Overstreet DH, Rezvani AH, Pucilowski O, Janowsky DS (1994) 5-HT receptors: implications for the neuropharmacology of alcohol and alcoholism. Alcohol Alcohol Suppl 2:207-212
41. Overstreet DH, Knapp DJ, Breese GR (2002) Accentuated decrease in social interaction in rats repeatedly withdrawn from ethanol. Alcohol Clin Exp Res 26:1259-1268
42. 2A/2C receptors and these receptor-linked phosphoinositide system by ethanol. Behav Brain Res 73:235-238
43. Pandey SC, Piano MR, Schwertz DW, Davis JM, Pandey GN (1992) Effect of ethanol administration and withdrawal on serotonin receptor subtypes and receptor-mediated phosphoinositide hydrolysis in rat brain. Alcohol Clin Exp Res 16:1110-1116
44. Soloff PH, Lynch KG, Moss HB (2000) Serotonin, impulsivity, and alcohol use disorders in the older adolescent: a psychobiological study. Alcohol Clin Exp Res 24:1609-1619
45. Stahl S (1997) Mixed depression and anxiety: serotoninta receptors as a common pharmacologic link. J Clin Psychiatry 58:20-26
46. Strowig AB (2000) Relapse determinants reported by men treated for alcohol addiction: the prominence of depressed mood. J Subst Abuse Treat 19:469-474
47. Tollefson GD, Montagu-Clouse J, Tollefson SF (1992) Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 12:19-25
48. Ulrichsen J (1991) Alterations in serotonin receptor subtypes in ethanol-dependent rats. Alcohol Alcohol 26:567-573
49. Wallis CJ, Rezazadeh SM, Lal H (1993) Role of serotonin in ethanol abuse. Drug Dev Res 30:178-188
50. Wiesbeck GA,Weijers HG, Chick J, Naranjo A, Boening J (1999) Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multi-center trial. Ritanserin in Alcoholism Work Group. Alcohol Clin Exp Res 23:230-235
51. Wiesbeck GA, Weijers HD, Chick J, Boening J (2000) The effects of ritanserin on mood, sleep, vigilance, clinical impression, and social functioning in alcohol-dependent individuals. Ritanserin in Alcoholism Work Group. Alcohol Alcohol 35:384-389
52. 1A receptors. J Clin Psychopharmacol 10:6S-12S